Study of Health in Pomerania

https://neurodegenerationresearch.eu/survey/study-of-health-in-pomerania/

Title of cohort

Study of Health in Pomerania

Acronym for cohort

SHIP / SHIP-Trend

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Henry

Name of Principal Investigator - Last name

Völzke

Address of institution -Institution

Institute for Community Medicine, University Clinics of Greifswald

Address of institution - Street address

Walther-Rathenau Str. 48

Address of institution - City

Greifswald

Address of institution - Postcode

17475

Country

Germany

Website

www.medizin.uni-greifswald.de/cm/fv/ship.html

Contact email

voelzke@uni-greifswald.de

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

SHIP assesses the prevalence and incidence of common risk factors, subclinical disorders and clinical diseases and investigates associations among risk factors, subclinical disorders and clinical diseases.

Q2b. What distinguishes this cohort from other population cohorts?
Q3a. i) Number of publications that involve use of your cohort to date

0

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

20

Q4a. Study criteria: what is the age range of participants at recruitment? To:

79

Q4b. Study criteria: what are the inclusion criteria?

German nationality, place of residence in Vorpommern

Q4c. Study criteria: what are the exclusion criteria?

None

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

5,001-10,000 participants

Q6a. Please describe what measures are used to characterise participants

Interview, extensive medical examination, questionnaires, imaging (e.g. ultrasound, echocardiography, mri)

Q6b. Are there additional measures for participants with a clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify
Q7. What is the study design (select all that apply)?

Prospective cohort

Q8. Are your cases matched by

Other health assessment

Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date

01/01/1997

Q10a. ii) Please enter the data collection end date
Q10a. iii) Is data collection for this study

Data collection ongoing|Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Is data collected
Other please specify here
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?
Q13a. Please give information on the format and availability of data stored in a database (1)
% available
Q13a. Please give information on the format and availability of data stored in a database (2)
% available
Q13a. Please give information on the format and availability of data stored in a database (3)
% available
Q13a. Please give information on the format and availability of data stored in a database (4)
% available
Other (please specify)

% available
Q13b. Please give information on the format and availability of data held as individual records (1)
% available
Q13b. Please give information on the format and availability of data held as individual records (2)
% available
Q13b. Please give information on the format and availability of data held as individual records (3)
% available
Q13b. Please give information on the format and availability of data held as individual records (4)
% available
Please specify language used
Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Formal application necessary

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Formal application necessary , under restrictive circumstances

Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?

No

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
Germany

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A